H.C. Wainwright reiterated coverage on BioNTech with a new price target

6/5/25 11:30:01 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

H.C. Wainwright reiterated coverage of BioNTech with a rating of Buy and set a new price target of $145.00 from $134.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BNTX

Date	Price Target	Rating	Analyst
6/5/2025	$134.00 → $145.00	Buy	H.C. Wainwright
5/29/2025	$110.00	Neutral	Goldman
3/13/2025	$145.00	Buy	Citigroup
1/10/2025	$172.00	Buy	Truist
12/11/2024	$170.00	Overweight	Wells Fargo
12/2/2024		Outperform	BMO Capital Markets
11/19/2024	$130.00	Buy	Berenberg
11/19/2024	$110.00 → $125.00	In-line → Outperform	Evercore ISI